According to NICE guideline NG28, GLP-1 receptor agonists like Rybelsus may be appropriate as a second-line or third-line option when: Metformin is contraindicated or not tolerated The patient has a body mass index (BMI) of 35 kg/m or higher (adjusted for ethnicity), or there are specific psychological or medical problems associated with obesity Weight loss would benefit other significant obesity-related comorbidities Patients who strongly prefer oral medication over injectable therapies may be suitable candidates for Rybelsus
Holst, rskov, Vagn Nielsen, Schwartz)
doi: 10.1016/j.bbagen.2012.09.008 80 MartinovM
To learn more about how we can assist you in managing ADHD, visit our website at Spark Mental Health.
What results can I expect, and how soon will I see them
[DOI] [PubMed] [Google Scholar] 39.Franco R., Schoneveld O.J., Pappa A., Panayiotidis M.I